American Century Companies Inc. Takes $8.91 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

American Century Companies Inc. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 346,572 shares of the company's stock, valued at approximately $8,907,000. American Century Companies Inc. owned 0.38% of NewAmsterdam Pharma as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at about $80,000. Quarry LP increased its position in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC increased its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after acquiring an additional 7,199 shares during the period. XTX Topco Ltd acquired a new stake in shares of NewAmsterdam Pharma in the third quarter valued at $187,000. Finally, HB Wealth Management LLC purchased a new position in NewAmsterdam Pharma in the fourth quarter valued at $224,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Up 0.3 %

NAMS traded up $0.05 on Monday, reaching $15.86. The company had a trading volume of 1,548,847 shares, compared to its average volume of 568,413. NewAmsterdam Pharma has a 1 year low of $10.04 and a 1 year high of $27.29. The stock has a market capitalization of $1.74 billion, a PE ratio of -6.10 and a beta of -0.01. The stock has a 50-day moving average price of $21.00 and a 200-day moving average price of $21.35.

Remove Ads

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James N. Topper acquired 1,135 shares of the company's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on NAMS shares. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC reduced their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Finally, Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.